drugset / Trial / NCT00053326

Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma

NCT00053326

Phase 2 Completed 70 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well fenretinide works in treating children with recurrent or resistant neuroblastoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Timeline

Start
2003-05
Primary completion
2006-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject fenretinide Small molecule Oral

Indications